Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITRATION: LCZ696 in Heart Failure
NCT01922089Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Started Nov 2013; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT01922089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01922089.